Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

Stock Information for Trevena Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Trevena Inc.

Trevena Announces Reverse Stock Split
Trevena Reports Second Quarter 2024 Results and Provides Business Update
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Trevena Reports First Quarter 2024 Results and Provides Business Update
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - ILMN
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.